Evofem Biosciences Inc. (OTCMKTS:EVFM) Releases Results from Phase 3 EVOGUARD Clinical Trial

October 12, 2022

Evofem Biosciences Inc. (OTCMKTS:EVFM) announced updates on October 11, 2022, regarding the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women. Unfortunately, the trial didn’t accomplish its endpoints. Trading Data On Tuesday, EVFM stock decreased 4.71% to $0.1639 with more than 956.04K shares, compared to its average volume of 8.91 million shares. The stock moved within a range of $0.1611…

Read More >>